MEA Drug modeling software Market - Industry Trends and Forecast to 2030

MEA Drug modeling software Market - Industry Trends and Forecast to 2030

The drug modeling software market is expected to reach USD 16,808.81 million by 2030 from USD 8,504.35 million in 2022, growing at a CAGR of 9.2% during the forecast period of 2023 to 2033.

Market Segmentation:
Middle East and Africa Drug Modeling Software Market, By Component (Software, and Services), Operating System (Windows, Linux, Mac OS, and Others), Deployment Mode (Cloud Based, Hybrid Based, and On Premises), Enterprise Size(Large Enterprise Size, Small and Medium Enterprise Size), Application (Graphical Molecular Modeling, Gene Sequence Analysis, Protein Modeling, Modeling Crystal Structures, Cheminformatics, High Throughput Virtual Screening, Gas and Solution Phase Reaction, Medical Imaging, and Others), Purchase Model (Subscription Based, and One- Time License), End User( Pharmaceutical and Biotechnology Companies, Contract Research Organization, Research Institutes, Regulatory Authorities, and Others), Country (South Africa , Saudi Arabia , UAE , Egypt, Israel , Oman , Bahrain , Kuwait , Qatar , Rest of Middle East and Africa) - Industry Trends and Forecast to 2030

Overview of Drug Modeling Software Market Dynamics:

Driver
• Rising drug discovery and development activities

Restrain

• Lack of quality data base

Opportunity

• Cloud computing and big data analytics in drug modelling

Market Players:

The key market players operating in the drug modeling software market are listed below:

• Dotmatics
• BC Platforms
• InSilicoTrials Technologies.
• VeriSIM Life., Atomwise Inc.
• Certara, USA.
• GENECODE
• Cresset., and Nanome Inc.
• SIMULATIONS PLUS.
• Dassault Systèmes
• Scripps Research
• XtalPi Inc.
• Xybion
• ArgusLab
• Schrödinger, Inc.